AMNEAL PHARMACEUTICALS, INC.
In the published model solve dated 2026-Q2, anchored at $17.44, AMNEAL PHARMACEUTICALS, INC. (AMRX) is priced for +6.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Three businesses share one roof here: a complex-generics arm that closed 2025 with ⟦61 products with a pending ANDA and another 43 products in various stages of development in our pipeline, 95% of which are non-oral solid products⟧, a small branded Specialty franchise built around the Parkinson's therapy CREXONT, and AvKARE, a government and institutional distributor supplying roughly a quarter of company revenue. • Leverage governs everything else: net debt of $2.37 billion sits at 5.6 times
Is AMRX overvalued? See what's priced in →
304 institutional managers reported holding AMRX in 13F filings for the quarter ended 2026-03-31. Together they hold about 48% of the company; the top 10 hold 29%. 70 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 7.9M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AMRX's share count grew 112.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at AMRX over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AMRX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +4.3% | +70.2% |
| 2023-08-09 | +22.3% | -0.7% |
| 2023-11-10 | -3.6% | +28.0% |
| 2024-03-15 | -0.9% | +24.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AMRX's latest 8-K filings: 2026-08-10 (items 1.01, 2.01, 2.03, 3.02, 7.01, 9.01); 2026-08-03 (items 1.01); 2026-07-31 (items 5.07); 2026-07-30 (items 2.02, 7.01, 9.01); 2026-05-07 (items 5.07).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.